Skip to main content

Table 2 MRI lesion volumes at Week 96

From: Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial

Mean change from baseline (SD) Delayed treatment Peginterferon beta-1a
Every 4 weeks Every 2 weeks
Patients with available data, n 391 389 406
T2 hyperintense lesion volume, cm3 0.617 (2.2341) 0.362 (2.6841) -0.231 (1.6103)a*
T1 hypointense lesion volume, cm3 0.869 (1.6907) 0.914 (2.4103) 0.478 (1.2417)*
Gd + lesion volume, cm3 -0.135 (0.5478) -0.164 (0.8676) -0.113 (0.4460)
  1. Gd+ gadolinium-enhancing lesions; SD standard deviation *p < 0.0001, p = 0.046 versus delayed treatment by Wilcoxon rank-sum test a n = 407